← Leaderboards
Elizabeth Mary Swisher
Fred Hutchinson Cancer Center
$14,985,539
Attributed
$15,665,135
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.7M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,665,135 · 8
By mechanism
R01$7,768,435 · 4
U01$5,804,010 · 1
P50$1,359,193 · 1
K08$657,315 · 1
P30$76,182 · 1
Top collaborators
- Toshiyasu Taniguchi5 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Cecilia C Yeung$2,137,399
- Cyrus M Ghajar$4,796,533
Others in their field
Top investigators on “Mutation”
- Richard A Gibbs · Baylor College Of Medicine$276,143,183
- David Heimbrook · Leidos Biomedical Research, Inc.$175,834,894
- Randall J Bateman · Washington University$154,391,630
- Eric Martin McDade · Washington University$96,219,353
- Stacey Gabriel · Massachusetts Institute Of Technology$95,141,374
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,475,056
Research focus
MutationMalignant NeoplasmsBrca1 GeneCellsResponseMalignant Neoplasm Of OvaryOvarian CarcinomaSpecimenBrca2 GeneAllelesChemotherapyGenesPlatinumWomanMammalian OviductsResistanceDna RepairCancer CellRecurrenceCancer TypePeritonealCostMethylationMutation Analysis
Grant awards (29)
Clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian cancer$648,957
R01 · FY2025 · CA · contact PI
Clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian cancer$616,508
R01 · FY2024 · CA · contact PI
Combined Methylation and Mutation to Predict Response to PARP Inhibitors$475,615
R01 · FY2024 · CA · contact PI
Research Program: Breast & Ovary Cancers$76,182
P30 · FY2024 · CA · contact PI
Clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian cancer$648,956
R01 · FY2023 · CA · contact PI
Combined Methylation and Mutation to Predict Response to PARP Inhibitors$585,331
R01 · FY2023 · CA · contact PI
Combined Methylation and Mutation to Predict Response to PARP Inhibitors$596,715
R01 · FY2022 · CA · contact PI
Methylation and Mutation Assay to Personalize PARP Inhibitor Therapy$455,032
R01 · FY2022 · CA · contact PI
Combined Methylation and Mutation to Predict Response to PARP Inhibitors$620,421
R01 · FY2021 · CA · contact PI
Methylation and Mutation Assay to Personalize PARP Inhibitor Therapy$445,658
R01 · FY2021 · CA · contact PI
Combined Methylation and Mutation to Predict Response to PARP Inhibitors$645,181
R01 · FY2020 · CA · contact PI
Methylation and Mutation Assay to Personalize PARP Inhibitor Therapy$459,533
R01 · FY2020 · CA · contact PI
Implementing the moon: Getting genomic testing to the public$134,882
U01 · FY2020 · CA · contact PI
Implementing the moon: Getting genomic testing to the public$5,669,128
U01 · FY2019 · CA · contact PI
Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium$295,150
R01 · FY2013 · CA · contact PI
Clinical Implication of the Acquisition of BRCA1/2 Function in BRCA1/2-Deflcient$262,827
P50 · FY2013 · CA
Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium$313,989
R01 · FY2012 · CA · contact PI
Clinical Implication of the Acquisition of BRCA1/2 Function in BRCA1/2-Deflcient$280,661
P50 · FY2012 · CA
Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium$313,989
R01 · FY2011 · CA · contact PI
Clinical Implication of the Acquisition of BRCA1/2 Function in BRCA1/2-Deflcient$257,007
P50 · FY2011 · CA
Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium$323,700
R01 · FY2010 · CA · contact PI
Clinical Implication of the Acquisition of BRCA1/2 Function in BRCA1/2-Deflcient$273,694
P50 · FY2010 · CA
Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium$323,700
R01 · FY2009 · CA · contact PI
Clinical Implication of the Acquisition of BRCA1/2 Function in BRCA1/2-Deflcient$285,004
P50 · FY2009 · CA
Genetic and Epigenetic Markers in Ovarian Cancer$131,463
K08 · FY2006 · CA · contact PI
Genetic and Epigenetic Markers in Ovarian Cancer$131,463
K08 · FY2005 · CA
Genetic and Epigenetic Markers in Ovarian Cancer$131,463
K08 · FY2004 · CA
Genetic and Epigenetic Markers in Ovarian Cancer$131,463
K08 · FY2003 · CA
Genetic and Epigenetic Markers in Ovarian Cancer$131,463
K08 · FY2002 · CA